Bolt Biotherapeutics, Inc.
Clinical-stage biotech developing immuno-oncology therapies using the innate immune system.
BOLT | US
Overview
Corporate Details
- ISIN(s):
- US0977021049
- LEI:
- Country:
- United States of America
- Address:
- 900 CHESAPEAKE DRIVE, 94063 REDWOOD CITY
- Website:
- https://boltbio.com/
- Sector:
- Manufacturing
Description
Bolt Biotherapeutics is a clinical-stage biotechnology company developing immuno-oncology therapies to treat cancer. The company's approach leverages the innate immune system, particularly myeloid cells, to create a therapeutic anti-tumor response. Its proprietary Boltbody™ Immune-stimulating Antibody Conjugate (ISAC) platform combines tumor-targeting antibodies with immune-stimulating agents. This technology is designed to repolarize tumor-supportive immune cells, such as macrophages, into tumor-destructive ones, while also activating the adaptive immune system. The company's pipeline includes multiple candidates generated from the ISAC platform and other novel approaches. A key candidate, BDC-3042, is a first-in-class Dectin-2 agonist antibody being evaluated in clinical trials.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Bolt Biotherapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Bolt Biotherapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Bolt Biotherapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
